OB/GYN Clinical Alert (Vol. 32, No. 5) – September 1, 2015

Read the Disclosure Information Below, then click “Continue” to begin testing.

Release date: September 2015

Valid through: September 2018

Target Audience

This activity is intended for the obstetrician and gynecologist.

Subjects

  • Handheld ultrasound for assessing fetal size
  • Good news for a change: No association of hormonal replacement therapy with breast cancer before age 50
  • When do combined oral contraceptives start working after ulipristal acetate emergency contraception?
  • Environmental influences on male reproductive function

Objectives

  • Explain the latest data regarding diagnosis and treatment of various diseases affecting women
  • Discuss new data concerning prenatal care, neonatal health, and complications arising in pregnancy and the perinatal period
  • Discuss the advantages, disadvantages, and cost-effectiveness of new testing procedures in women

Credit Available

Physicians

  • Maximum of 2.25 AMA PRA Category 1 Credits

Sponsor

This activity is sponsored by AHC Media.

Accreditation Statement

AHC Media is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation

Physicians

AHC Media designates this enduring material for a maximum of 2.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Faculty Listing

Authors

John C. Hobbins, MD, Professor, Department of Obstetrics and Gynecology, University of Colorado School of Medicine, Aurora

Jeffrey T. Jensen, MD, MPH, Leon Speroff Professor and Vice Chair for Research, Department of Obstetrics and Gynecology, Oregon Health & Science University, Portland

Rebecca H. Allen, MD, MPH, Assistant Professor, Department of Obstetrics and Gynecology, Warren Alpert Medical School of Brown University, Women and Infants Hospital, Providence, RI

Robert W. Rebar, MD, Professor and Chair, Department of Obstetrics and Gynecology, Western Michigan Homer Stryker MD School of Medicine, Kalamazoo

Editors

Medical Editor: Jeffrey T. Jensen, MD, MPH

AHC Media Executive Editor: Leslie G. Coplin

Associate Managing Editor: Jonathan Springston

Financial Disclosure

Rebecca Allen, MD, reports she is a Nexplanon trainer for Merck, a Liletta trainer for Actavis, and on the advisory board for Bayer, Actavis, and Vermillion. John C. Hobbins, MD, and Robert W. Rebar, MD, report no financial relationships relevant to this field of study.

OB/GYN Clinical Alert's Editor, Jeffrey T. Jensen, MD, MPH, is a consultant for and receives grant/research support from HRA Pharma, Bayer Healthcare, Merck, Agile Pharm, Population Council, AbbVie, Evofem and ContraMed; and is a consultant for Teva Pharmaceuticals and Microchips.

Peer Reviewer Catherine Leclair, MD, Executive Editor Leslie G. Coplin, and Associate Managing Editor Jonathan Springston report no financial relationship to this field of study.

Copyright 2015, AHC Media. All rights reserved.